Targeted attack on lung cancer before surgery
NCT ID NCT05472623
Summary
This study aimed to test whether giving a targeted drug called adagrasib, alone or with an immunotherapy drug (nivolumab), before surgery could help people with a specific type of lung cancer. It was for patients with non-small cell lung cancer that could be surgically removed and had a particular genetic change called KRAS G12C. The goal was to see if this treatment could shrink or eliminate the tumor before surgery to improve outcomes. The study was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Johns Hopkins
Baltimore, Maryland, 21231, United States
Conditions
Explore the condition pages connected to this study.